RAD51 Testing in Patients with Early HER2-Negative Breast Cancer and Homologous Recombination Deficiency: A <i>Post Hoc</i> Analysis of the GeparOLA Trial
In a preselected population with HRD, according to a genetic test, RAD51 testing identifies patients with different pCR rates under PARP inhibitor-based or platinum-based therapies. Future biomarker-driven studies should consider this information to refine stratification factors and to improve patient selection.
Authors
- Marion van Mackelenbergh (ORCID: https://orcid.org/0000-0002-1084-5897)
- Frederik Marmé (ORCID: https://orcid.org/0000-0002-6591-3367)
- Elmar Stickeler (ORCID: https://orcid.org/0000-0002-9715-7260)
- Peter A. Fasching (ORCID: https://orcid.org/0000-0003-4885-8471)
- Christoph Uleer (ORCID: https://orcid.org/0000-0002-7937-8182)
- Natalie Filmann (ORCID: https://orcid.org/0000-0003-0424-2317)
- Thomas Karn (ORCID: https://orcid.org/0000-0002-3264-6573)
- Guillermo Villacampa (ORCID: https://orcid.org/0000-0003-4868-6585)
- Christian Schem (ORCID: https://orcid.org/0000-0001-8606-3077)
- Carsten Denkert (ORCID: https://orcid.org/0000-0002-2249-0982)
- Gabriele Doering (ORCID: https://orcid.org/0009-0006-2216-1130)
- Andrea Stefek (ORCID: https://orcid.org/0000-0003-3596-8188)
- Valentina Nekljudova (ORCID: https://orcid.org/0000-0002-2801-7387)
- Peter Klare
- Alba Llop‐Guevara (ORCID: https://orcid.org/0000-0002-7913-9472)
- Violeta Serra (ORCID: https://orcid.org/0000-0001-6620-1065)
- Bärbel Felder (ORCID: https://orcid.org/0009-0001-0072-0097)
- Andrea Herencia-Ropero (ORCID: https://orcid.org/0000-0002-1699-0251)
- Judith Balmañà (ORCID: https://orcid.org/0000-0002-0762-6415)
- Tanja Fehm (ORCID: https://orcid.org/0000-0002-4926-0108)
- Sibylle Loibl (ORCID: https://orcid.org/0000-0001-6488-4958)
- Volkmar Mueller (ORCID: https://orcid.org/0000-0003-4231-7906)
Institutions
- Goethe University Frankfurt (DE)
- University of Hildesheim (DE)
- Universität Hamburg (DE)
- Philipps University of Marburg (DE)
- University of Mannheim (DE)
- University of Bremen (DE)
- Heidelberg University (DE)
- Universitätsklinikum Gießen und Marburg (DE)
- Deutsches Archäologisches Institut, Zentrale (DE)
- University Hospital Heidelberg (DE)
- Universitätsklinikum Erlangen (DE)
- Düsseldorf University Hospital (DE)
- Klinik für Frauenheilkunde (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- University Hospital Schleswig-Holstein (DE)
- Universitätsklinikum Aachen (DE)
- Mammazentrum Hamburg (DE)
- Cardiovascular Center Frankfurt (DE)
- Vall d'Hebron Hospital Universitari (ES)
- German Breast group (DE)
- University Hospital Frankfurt (DE)
- Praxis für Hämatologie und Onkologie (DE)
- Comprehensive Cancer Center Erlangen (DE)
- Hochschule Magdeburg-Stendal (DE)
- University Medical Centre Mannheim (DE)
- Krankenhaus Jerusalem (DE)
- Vall d'Hebron Institute of Oncology (ES)
- Heinrich Heine University Düsseldorf (DE)
- Frankfurt University of Applied Sciences (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-12-30
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-3148
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.28